Cargando…

PM330. A Proof-of-concept Phase IIa Trial on an Investigational New Drug for Psychostimulant Use Disorder Treatment

Detalles Bibliográficos
Autor principal:	Lee, Tong H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5616266/ http://dx.doi.org/10.1093/ijnp/pyw041.330

Ejemplares similares

Psychostimulants and Movement Disorders
por: Asser, Andres, et al.
Publicado: (2015)

Psychostimulant Drugs and Neuroplasticity
por: Fernandez-Espejo, Emilio, et al.
Publicado: (2011)

Seamless phase IIa/IIb adaptive design with the same primary endpoint for proof of concept and dose finding
por: Yuan, Jiacheng, et al.
Publicado: (2018)

A feasibility and safety study of afamelanotide in acute stroke patients – an open label, proof of concept, phase iia clinical trial
por: Stanislaus, Vimal, et al.
Publicado: (2023)

330. Outpatient Parenteral Antimicrobial Therapy in People who Inject Drugs
por: Hawes, Armani, et al.
Publicado: (2023)

Evidence base to support using prescribed psychostimulants to treat psychostimulant use disorder is limited
por: Bahji, Anees, et al.
Publicado: (2023)

First episode psychosis and the use of psychostimulants - a case report
por: Teixeira, T., et al.
Publicado: (2021)

Differences in addictive beliefs in people with psychostimulant addiction and in opioid addicts
por: Yan, Y., et al.
Publicado: (2022)

Autologous Stem Cells in Achilles Tendinopathy (ASCAT): protocol for a phase IIA, single-centre, proof-of-concept study
por: Goldberg, Andrew J, et al.
Publicado: (2018)

Dysfunction of the Neurovascular Unit by Psychostimulant Drugs
por: Vo, Tam Thuy Lu, et al.
Publicado: (2023)

Clinical and biochemical parameters associated with substance-induced psychotic disorder: which differences between alcohol, cannabis and psychostimulants
por: Nosari, G., et al.
Publicado: (2023)

330. Survival of HIV-Positive Patients with Hemophagocytic Lymphohistiocytosis
por: Brown, Timothy J, et al.
Publicado: (2019)

Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254( )
por: Spinner, Christoph D, et al.
Publicado: (2022)

A phase IIa proof-of-concept, placebo-controlled, randomized, double-blind, crossover, single-dose clinical trial of a new class of bronchodilator for acute asthma
por: Swystun, Veronica, et al.
Publicado: (2018)

Interaction of Diamine Oxidase with Psychostimulant Drugs for ADHD Management
por: Tobajas, Yaiza, et al.
Publicado: (2023)

147. Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, in the Treatment of Candidemia: Results from a Phase 2 Proof of Concept Trial
por: Pappas, Peter, et al.
Publicado: (2020)

330. Head and Spine Injuries Increase Risk of Streptococcus pneumoniae Meningitis in Adults
por: Chu, Victoria, et al.
Publicado: (2018)

Culturomics to Investigate the Endometrial Microbiome: Proof-of-Concept
por: Vanstokstraeten, Robin, et al.
Publicado: (2022)

The Effects of Psychostimulant Drugs on Blood Brain Barrier Function and Neuroinflammation
por: Kousik, Sharanya M., et al.
Publicado: (2012)

Risk of Tics with Psychostimulants for ADHD
por: Millichap, J. Gordon
Publicado: (2015)

Binge eating and psychostimulant addiction
por: Blanco-Gandia, M Carmen, et al.
Publicado: (2021)

Role of Microglia in Psychostimulant Addiction
por: Machado da Silva, Maria Carolina, et al.
Publicado: (2023)

Trauma research at the scene of injury – proof of concept through collaboration
por: Clarkson, Aisling, et al.
Publicado: (2015)

The Stage-Based Model of Addiction—Using Drosophila to Investigate Alcohol and Psychostimulant Responses
por: Cummins-Beebee, Pearl N., et al.
Publicado: (2023)

Attention-deficit hyperactivity disorder and use of psychostimulants among children in Turkey
por: Aras, Sahbal, et al.
Publicado: (2007)

Critical View on the Usage of Ribavirin in Already Existing Psychostimulant-Use Disorder
por: Petković, Branka, et al.
Publicado: (2020)

Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs
por: Han, Dawn D, et al.
Publicado: (2006)

The Role of Adenosine Receptors in Psychostimulant Addiction
por: Ballesteros-Yáñez, Inmaculada, et al.
Publicado: (2018)

The Use of Drosophila to Understand Psychostimulant Responses
por: Philyaw, Travis James, et al.
Publicado: (2022)

The role of serotoninergic system in psychostimulant effects
por: Taracha, Ewa
Publicado: (2021)

The Therapeutic Potential of Amphetamine-like Psychostimulants
por: Pires, Bruno, et al.
Publicado: (2023)

330 grabados originales
por: Manilla, Manuel
Publicado: (1971)

A proof-of concept randomized controlled trial to show that the antidepressant effect of psilocybin does not require a psychedelic experience: study protocol
por: Husain, M. I., et al.
Publicado: (2023)

Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder
por: Connor, Kathryn M, et al.
Publicado: (2017)

A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer
por: Shafique, Michael, et al.
Publicado: (2019)

Data Mining of Free-Text Responses: An Innovative Approach to Analyzing Patient Perspectives on Treatment for Chronic Rhinosinusitis with Nasal Polyps in a Phase IIa Proof-of-Concept Study for Dupilumab
por: Khan, Asif H, et al.
Publicado: (2021)

91. Establishing Proof of Concept for a Bivalent RSVpreF Subunit Vaccine for Maternal Immunization
por: Simões, Eric A F, et al.
Publicado: (2022)

Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof‐of‐Concept Trial
por: Videnovic, Aleksandar, et al.
Publicado: (2021)

Comparisons of Analysis Methods for Proof-of-Concept Trials
por: Karlsson, K E, et al.
Publicado: (2013)

Dysregulation of Acetylation Enzymes in Animal Models of Psychostimulant use Disorders: Evolving Stories
por: Cadet, Jean Lud
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5j2173k92dee6m4k515gi3b1i6